Tag Archives: Novartis

Amgen likely win Enbrel patent appeal, but Novartis scored some points: analyst

Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but analysts figure Amgen still holds an edge. At an appeals hearing Wednesday, judges heard arguments from Amgen and Novartis’ Sandoz unit over patents protecting big-selling Enbrel until 2029. While Sandoz’s… Read More »

Novartis’ SMA gene therapy Zolgensma could struggle to hit blockbuster territory: report

Despite an ongoing soap opera surrounding Zolgensma, Novartis’ gene therapy for spinal muscular atrophy (SMA), Wall Street analysts are optimistic about the product overall, with some estimating peak sales north of $ 2 billion a year. JPMorgan analysts surveyed 26 physicians who treat SMA and came to a vastly different conclusion: Concerns about the efficacy of… Read More »

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH (Reuters) – Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance. FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Jan. 25, 2017. REUTERS/Arnd… Read More »